Rhythm Pharmaceuticals (RYTM) Given News Impact Score of 0.22

Media stories about Rhythm Pharmaceuticals (NASDAQ:RYTM) have been trending somewhat positive on Sunday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Rhythm Pharmaceuticals earned a news impact score of 0.22 on Accern’s scale. Accern also gave media coverage about the company an impact score of 44.7847419574083 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the headlines that may have impacted Accern Sentiment’s analysis:

How to Become a New Pot Stock Millionaire

RYTM has been the topic of several research reports. BidaskClub lowered Rhythm Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, December 29th. Needham & Company LLC restated a “buy” rating and set a $32.00 price target on shares of Rhythm Pharmaceuticals in a research note on Monday, February 26th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $31.25.

Rhythm Pharmaceuticals (NASDAQ RYTM) traded down $0.74 during mid-day trading on Friday, hitting $22.82. The stock had a trading volume of 214,181 shares, compared to its average volume of 71,022. Rhythm Pharmaceuticals has a 52 week low of $21.38 and a 52 week high of $33.81.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its quarterly earnings data on Monday, March 12th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.14. sell-side analysts predict that Rhythm Pharmaceuticals will post -2.3 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This article was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/3274968/rhythm-pharmaceuticals-rytm-given-news-impact-score-of-0-22.html.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.

Insider Buying and Selling by Quarter for Rhythm Pharmaceuticals (NASDAQ:RYTM)

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Smart Sand  Expected to Post Earnings of $0.08 Per Share
Smart Sand Expected to Post Earnings of $0.08 Per Share
JetPay  Getting Favorable News Coverage, Accern Reports
JetPay Getting Favorable News Coverage, Accern Reports
Glen Burnie Bancorp  Receives News Sentiment Rating of -0.08
Glen Burnie Bancorp Receives News Sentiment Rating of -0.08
MKS Instruments  Releases Q2 Earnings Guidance
MKS Instruments Releases Q2 Earnings Guidance
Vipshop  versus Qurate Retail Group  Critical Contrast
Vipshop versus Qurate Retail Group Critical Contrast
Reviewing Chunghwa Telecom  and Cellcom
Reviewing Chunghwa Telecom and Cellcom


© 2006-2018 Ticker Report. Google+.